Jefferies raised the firm’s price target on Enhabit (EHAB) to $12 from $11 and keeps a Buy rating on the shares. Following clarity on the CMS home health rule, the firm reiterates its Buy rating on Enhabit citing improved reimbursement visibility, combined with ongoing cost savings initiatives, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHAB: